DENTSPLY SIRONA (XRAY) AI Stock Analysis

• Market Cap: $2.66B
• Dividend Yield: 4.05%
• Average Volume (3M): 3.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: -5.61%
• EPS Growth: -921.99%
• Country: US
• Employees: 14,000
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.43
• Shares Outstanding: 199,293,380
• 10 Day Avg. Volume: 2,790,475
• 30 Day Avg. Volume: 3,065,842
• PEG Ratio: 0.03
• Price to Book (P/B): 1.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.21
• Enterprise Value/Market Cap: 1.93
• Enterprise Value/Revenue: 0.33
• Enterprise Value/Gross Profit: 2.63
• Enterprise Value/Ebitda: 26.01
• 1Y Price Target: $17.65
• Price Target Upside: 11.64% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 15

DENTSPLY SIRONA's overall stock score reflects significant financial and operational challenges, including declining revenue and high leverage. Technical indicators suggest bearish trends, compounding the company’s difficulties. While strategic initiatives and a high dividend yield offer some positives, they are outweighed by negative earnings and cautious future guidance, resulting in a lower overall score.

Positive Factors

Earnings Performance

1Q EPS of $0.43 was ahead of our estimate on higher revenues and profitability.

Margin Expansion

Expanding margins show the benefit of management execution and valuation creates an attractive risk/reward.

Operating Leverage

XRAY's organic growth in key segments is stabilizing with cost efficiencies also driving more operating leverage than anticipated.

Negative Factors

Leadership Uncertainty

Investor focus is on the sudden and unexpected Interim CFO departure, which may give investors pause as we think about conviction in its latest 2025 guidance.

Revenue Decline

Reported revenue declined 7.7%, ahead of our estimate and consensus, including -4.4% organic growth.

Tariffs and Macro Concerns

Tariffs and macro concerns are weighing on results.

DENTSPLY SIRONA Business Overview & Revenue Model

Company Description

DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed clear aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products. The Consumables segment offers endodontic products comprising drills, filers, sealers, irrigation needles, and other tools or single-use solutions, which support root canal procedures; restorative products that include artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. It also provides small equipment products, which comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride. The company was founded in 1877 and is headquartered in Charlotte, North Carolina.

How the Company Makes Money

DENTSPLY SIRONA generates revenue primarily through the sale of its dental equipment and consumables. The company's key revenue streams include the sale of dental instruments, imaging systems, treatment centers, dental laboratory products, and other related consumables. Additionally, DENTSPLY SIRONA benefits from a strong network of distributors and direct sales channels, allowing it to reach a broad customer base globally. Strategic partnerships and collaborations with dental professionals, academic institutions, and other healthcare entities further bolster its market presence and sales. The company's focus on innovation and technology development, such as digital dentistry and integrated solutions, also contributes to its revenue growth by meeting the evolving demands of the dental industry.

DENTSPLY SIRONA Financial Statement Overview

Summary

DENTSPLY SIRONA has faced challenges with declining revenue and profitability, as reflected in the income statement. The balance sheet shows increased leverage, posing potential financial risks. While the cash flow statement indicates some resilience in cash generation, continued negative income could threaten long-term stability. Financial pressures demand strategic actions.

Income Statement

DENTSPLY SIRONA has experienced significant revenue decline over the past years, with a decrease from $4.25 billion in 2021 to $3.79 billion in 2024. The company also shows a negative net income of $910 million in 2024, with net profit margins consistently negative. Although the gross profit margin remains relatively stable, EBIT and EBITDA margins have deteriorated, indicating challenges in operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has increased over the years, indicating higher leverage and potential financial risk. Stockholders' equity has decreased significantly, impacting the equity ratio. Despite this, the company's total assets remain robust, providing some stability.

Cash Flow

Operating cash flow has been relatively stable, with a slight increase in free cash flow in 2024. The free cash flow to net income ratio indicates a stronger cash position relative to earnings, despite negative net income. However, consistent negative net income presents a risk to sustainable cash flow generation.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.79B	3.96B	3.92B	4.25B	3.34B
	Gross Profit
1.96B	2.09B	2.13B	2.36B	1.66B
	EBIT
-879.00M	-85.00M	306.00M	622.00M	456.00M
	EBITDA
-532.00M	232.00M	-677.00M	972.00M	336.00M
	Net Income Common Stockholders
-910.00M	-132.00M	-950.00M	411.00M	-83.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
272.00M	334.00M	365.00M	339.00M	438.00M
	Total Assets
5.75B	7.37B	7.64B	9.22B	9.34B
	Total Debt
2.27B	2.30B	2.09B	2.24B	2.41B
	Net Debt
2.00B	1.97B	1.73B	1.90B	1.97B
	Total Liabilities
3.81B	4.08B	3.83B	4.18B	4.37B
	Stockholders Equity
1.94B	3.29B	3.81B	5.04B	4.97B
Cash Flow		Free Cash Flow
281.00M	228.00M	368.00M	515.00M	548.00M
	Operating Cash Flow
461.00M	377.00M	517.00M	657.00M	635.00M
	Investing Cash Flow
-197.00M	-89.00M	-138.00M	-358.00M	-1.11B
	Financing Cash Flow
-302.00M	-307.00M	-329.00M	-379.00M	490.00M

DENTSPLY SIRONA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 15.81
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRAY, the sentiment is Neutral. The current price of 15.81 is above the 20-day moving average (MA) of 13.64, above the 50-day MA of 14.48, and below the 200-day MA of 19.80, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 66.65 is Neutral, neither overbought nor oversold. The STOCH value of 74.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XRAY.

DENTSPLY SIRONA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	85 Outperform	$35.48B	27.02	25.81%	0.84%	9.54%	37.23%
COO	76 Outperform	$16.11B	38.96	5.25%	―	7.15%	41.96%
BDX	68 Neutral	$47.93B	31.91	5.97%	2.38%	5.84%	15.12%
HOLX	66 Neutral	$12.65B	23.96	11.77%	―	1.66%	21.95%
XRAY	53 Neutral	$2.66B	―	-34.47%	4.05%	-5.61%	-921.99%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.50%
BAX	50 Neutral	$15.35B	136.07	-8.96%	2.98%	-20.17%	-138.32%

DENTSPLY SIRONA Corporate Events

Dentsply Sirona CEO Takes on Interim CFO Role

On May 8, 2025, Dentsply Sirona announced that Herman V. Cueto completed his role as interim CFO, with CEO Simon D. Campion temporarily assuming the financial officer duties. The company reported a 7.7% decrease in net sales for Q1 2025 compared to the previous year, impacted by foreign currency changes and a decline in Byte sales. Despite these challenges, Dentsply Sirona maintained its outlook for organic sales and adjusted EPS, emphasizing its commitment to long-term performance through transformational initiatives.

Spark’s Take on XRAY Stock

According to Spark, TipRanks’ AI Analyst, XRAY is a Neutral.

DENTSPLY SIRONA’s overall stock score reflects significant financial and operational challenges, including declining revenue and high leverage. Technical indicators suggest bearish trends, compounding the company’s difficulties. While strategic initiatives and a high dividend yield offer some positives, they are outweighed by negative earnings and cautious future guidance, resulting in a lower overall score.

To see Spark’s full report on XRAY stock, click here.

Dentsply Sirona Explores Strategic Options for Wellspect

On February 11, 2025, Dentsply Sirona announced it is evaluating strategic alternatives for its Wellspect Healthcare business, a leading provider in bladder and bowel management care products. This decision is part of the company’s broader transformation strategy aimed at unlocking value for stakeholders and refocusing efforts on its core dental business. Wellspect has shown strong growth in recent years and holds a significant position in the $2 billion continence care market. The review process does not have a set timeline and may or may not result in a transaction.